NCT03452579View on ClinicalTrials.gov

Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

May 21, 2018

Primary Completion Date

December 30, 2020

Study Completion Date

June 30, 2025

Conditions
Glioblastoma
Interventions
DRUG

Nivolumab

240mg

DRUG

Standard Dose Bevacizumab

10mg/kg

DRUG

Low Dose Bevacizumab

3mg/kg

Trial Locations (2)

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

David Peereboom

OTHER

NCT03452579 - Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM | Biotech Hunter | Biotech Hunter